About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals news and updates
Crinetics Pharmaceuticals, Inc. hired James Hassard as chief commercial officer on Mar 1st 22'.
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as chief commercial officer.
Jan 1, 2022 | globenewswire.comCrinetics Pharmaceuticals, Inc. hired Chris Robillard as chief business officer on Mar 21st 22'.
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Chris Robillard to the newly created position of chief business officer.
Jan 1, 2022 | crinetics.comCrinetics Pharmaceuticals, Inc. hired Caren Deardorf as board of directors on Mar 14th 22'.
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Caren Deardorf to the company’s board of directors.
Jan 1, 2022 | crinetics.comCrinetics Pharmaceuticals, Inc. hired Dana Pizzuti as chief development officer on Oct 3rd 22'.
Crinetics Pharmaceuticals Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer.
Oct 2, 2022 | biospace.com